Court Rejects Insulet Petition in EOFlow Legal Dispute
The denial of a rehearing keeps financial pressure on EOFlow as the medical device maker faces a strict delisting deadline.
Updated on Oct. 21, 2026 in Healthcare
Live Poll
Do you believe legal wins are enough to restore confidence in a company's financial future?
The U.S. Federal Circuit Court of Appeals has denied Insulet's request for an en banc rehearing in its ongoing trade secret litigation against EOFlow. This procedural ruling leaves in place an appellate decision that could jeopardize EOFlow's standing while the company navigates a critical financial improvement period in South Korea.
Why it matters
The case highlights the operational risk of prolonged intellectual property litigation, which has contributed to EOFlow's severe capital impairment. For operators, the dispute underscores how legal expenses and legal-related business delays can rapidly deteriorate a company's balance sheet and trigger delisting threats.
EOFlow faces significant financial strain, reporting 73.5 billion Korean won in operating losses and 91.9 billion Korean won in net losses. The firm, which recently completed a 26 billion Korean won rights offering, must navigate these deficits amid ongoing legal challenges.
The players
Insulet
A developer and manufacturer of wearable insulin pump technology with a significant global market share.
EOFlow
A South Korean medical device manufacturer specializing in wearable drug delivery systems.
Korea Exchange
The sole securities exchange operator in South Korea responsible for regulating listing standards and financial compliance.
Medtronic
A global leader in medical technology that previously considered an acquisition of EOFlow before withdrawing in 2023.
The details
The appellate court's decision centers on a statute of limitations argument, concluding that Insulet failed to file its trade secret claims within the required three-year window after the discovery of the alleged infringement. EOFlow’s business operations have been severely strained by these proceedings, compounded by the 2023 collapse of a planned acquisition by Medtronic. The company is currently under a conditional improvement period mandated by the Korea Exchange, requiring it to stabilize its capital structure by April 2027 to avoid being delisted from the stock exchange.
Timeline
2019: EOFlow launches its competing EOPatch product.
August 2023: Insulet initiates the trade secret lawsuit against EOFlow.
May 2026: The appeals court overturns a previous lower court judgment.
October 19, 2026: The court rejects Insulet's petition for an en banc rehearing.
April 8, 2027: The final deadline for EOFlow to complete its delisting improvement period.
Market Landscape
The ongoing litigation follows the 2023 collapse of the Medtronic-EOFlow acquisition, which left the firm without a strategic exit and burdened by mounting legal costs. This case reflects a broader trend of intensive patent and trade secret disputes within the medical device industry as manufacturers fight to protect market share in the wearable insulin space.
Operators in the medical technology sector should evaluate their own intellectual property defense strategies and the potential for long-term litigation to drain operational capital. Reviewing the robustness of internal trade secret protections and monitoring the financial health of partners or competitors involved in protracted legal disputes is essential.
The takeaway
Lengthy legal battles can destabilize even specialized technology providers by tying up essential capital and causing strategic uncertainty. Operators should track the litigation timelines and balance sheet health of key industry suppliers to anticipate potential shifts in market availability.
What happens next
Insulet has until January 2027 to file an appeal with the U.S. Supreme Court, while EOFlow is operating under a strict deadline to satisfy financial improvement requirements by April 8, 2027.
Further reading
For more on industry-wide regulatory and legal trends, see our coverage in Healthcare.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you believe legal wins are enough to restore confidence in a company's financial future?
